Natera, Inc. (NASDAQ:NTRA) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lessened its holdings in Natera, Inc. (NASDAQ:NTRA) by 17.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,259 shares of the medical research company’s stock after selling 4,205 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Natera were worth $3,207,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Creative Planning raised its holdings in Natera by 18.3% in the 3rd quarter. Creative Planning now owns 5,833 shares of the medical research company’s stock valued at $740,000 after buying an additional 904 shares during the period. Private Advisor Group LLC increased its position in shares of Natera by 5.2% during the third quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock valued at $346,000 after acquiring an additional 135 shares during the last quarter. International Assets Investment Management LLC raised its stake in shares of Natera by 9,755.3% in the 3rd quarter. International Assets Investment Management LLC now owns 14,980 shares of the medical research company’s stock valued at $1,902,000 after acquiring an additional 14,828 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Natera by 17.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 10,858 shares of the medical research company’s stock worth $1,378,000 after acquiring an additional 1,640 shares during the last quarter. Finally, Stephens Inc. AR purchased a new position in shares of Natera during the 3rd quarter worth approximately $258,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research analyst reports. TD Cowen boosted their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Guggenheim boosted their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. Craig Hallum raised their target price on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Sanford C. Bernstein lifted their target price on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, January 10th. Finally, Robert W. Baird increased their price target on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $172.69.

Insider Transactions at Natera

In other Natera news, Director Roelof Botha sold 87,473 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total value of $14,793,433.76. Following the transaction, the director now directly owns 1,224,787 shares in the company, valued at $207,135,977.44. This represents a 6.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Fesko sold 663 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the sale, the insider now owns 156,044 shares of the company’s stock, valued at $27,739,941.88. This represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 295,772 shares of company stock valued at $49,741,699. Corporate insiders own 7.60% of the company’s stock.

Natera Trading Down 0.7 %

Shares of NASDAQ:NTRA opened at $155.59 on Friday. The company has a market cap of $20.54 billion, a PE ratio of -88.40 and a beta of 1.66. The company’s 50 day moving average is $167.44 and its two-hundred day moving average is $146.95. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.